RecruitingPhase 2NCT04665739
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Studying Bronchial neuroendocrine tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Thomas A HopeAlliance for Clinical Trials in Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 70 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2033
Study locations (29)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Tower Cancer Research Foundation, Beverly Hills, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Torrance Memorial Physician Network - Cancer Care, Torrance, California, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
- University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04665739 on ClinicalTrials.govOther trials for Bronchial neuroendocrine tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07174583A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerIDEAYA Biosciences
- RECRUITINGNANCT07555210Pilot Study of Bone Mineral Density Changes During Anti-PD-1 ImmunotherapyJessica Mezzanotte Sharpe
- RECRUITINGPHASE1, PHASE2NCT05636618Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine TumorsPerspective Therapeutics
- RECRUITINGPHASE3NCT05522660Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung CancerETOP IBCSG Partners Foundation
- RECRUITINGPHASE1NCT04429087A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Boehringer Ingelheim
- ACTIVE NOT RECRUITINGPHASE1NCT02589522Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsNational Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT00068003Harvesting Cells for Experimental Cancer TreatmentsNational Cancer Institute (NCI)